PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRV
Post# of 77
(Total Views: 190)
Posted On: 08/03/2018 7:55:55 PM
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Advances Controlled Synthesis of Scorpion Venom Peptides for Brain Therapies
- PreveCeutical’s ‘Nature Identical™’ efforts aim to create consistently reproducible versions of found-in-nature therapeutics
- Company has begun engineering redesign phase of select identified peptides derived from famed scorpion venom
- Preventative therapeutics market expected to generate $196.9 billion in revenues by 2024, demonstrating alternative health products’ potential
PreveCeutical Medical Inc.’s (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) efforts to develop a synthesized and consistently reproducible ‘Nature Identical™’ scorpion venom, popular as a pain reliever and cancer therapy, has taken a new step toward marketability as the company commences work on re-engineering venom peptide components to stabilize them.
The biotech company based in British Columbia, Canada, has established its purpose as delivering organic and nature-inspired products to patients dealing with certain select ailments, in the hope of providing the patients with affirmative treatment and, through immune system support, preventing the maladies from occurring in those not yet afflicted. PreveCeutical’s interests extend specifically to type 2 diabetes and obesity, mild traumatic brain injury, cancer and pervasive pain.
PreveCeutical’s work to provide the benefits of Caribbean Blue Scorpion venom to patients with mild head injuries and glioblastoma, a highly-aggressive form of brain cancer, has established the company as having a novel, natural approach to treating less-commonly researched ailments. Caribbean Blue Scorpion venom has long had some popular medicinal use among people in several nations, and PreveCeutical’s aim is to provide a consistent, high-quality source that doesn’t require someone to milk scorpions regularly in order to establish a supply.
The company completed its first phase of R&D on the project earlier this year, identifying eight scorpion peptides of such a size and nature that PreveCeutical could redesign and synthesize them for potential use in Nature Identical™ products. The company has now begun Phase 2 of the project, which involves doing the peptide redesign work with the goal of improving the peptides’ stability, so they can maintain their potency while being employed against the brain maladies, according to a news release issued on July 31, 2018 (http://nnw.fm/zRQ3i).
“The Company’s research team is using state-of-the-art computer technology for its in-silico modelling and docking studies, against known brain cancer targets (e.g. Matrix metalloproteinases) to determine the structural features and amino acid sequences critical to their binding,” the news release states.
Once PreveCeutical establishes a library of highly stable peptides, the company will begin the third phase of the program in which it begins screening the Nature Identical™ peptides in cell-based glioblastoma models.
One of the company’s primary goals is to establish a novel drug delivery method by producing a Sol-gel compound that can be administered nasally, creating a pathway for medicines such as cannabidiol contained within the Sol-gel to reach the brain directly from the nose without having to travel the digestive tract and risking its weeding-out barriers.
Crystal Equity Research noted that the company shifted its potential “into a higher gear with its development pipeline” after successfully raising C$6.5 million ($4.9 million) in June for useable capital (http://nnw.fm/4Yj7v), as well as executing a five-for-one stock split that created the potential for greater liquidity. The research firm anticipates that preventative health care will continue to be a lucrative market, citing Grand View Research’s forecast for generating $196.9 billion in revenue by 2024 with a 15 percent CAGR.
“The recent capital raise provides some assurance that the R&D budget has sufficient support to reach milestones or at least produce relevant results,” Crystal Equity states.
For more information, visit the company’s website at www.PreveCeutical.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- PreveCeutical’s ‘Nature Identical™’ efforts aim to create consistently reproducible versions of found-in-nature therapeutics
- Company has begun engineering redesign phase of select identified peptides derived from famed scorpion venom
- Preventative therapeutics market expected to generate $196.9 billion in revenues by 2024, demonstrating alternative health products’ potential
PreveCeutical Medical Inc.’s (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) efforts to develop a synthesized and consistently reproducible ‘Nature Identical™’ scorpion venom, popular as a pain reliever and cancer therapy, has taken a new step toward marketability as the company commences work on re-engineering venom peptide components to stabilize them.
The biotech company based in British Columbia, Canada, has established its purpose as delivering organic and nature-inspired products to patients dealing with certain select ailments, in the hope of providing the patients with affirmative treatment and, through immune system support, preventing the maladies from occurring in those not yet afflicted. PreveCeutical’s interests extend specifically to type 2 diabetes and obesity, mild traumatic brain injury, cancer and pervasive pain.
PreveCeutical’s work to provide the benefits of Caribbean Blue Scorpion venom to patients with mild head injuries and glioblastoma, a highly-aggressive form of brain cancer, has established the company as having a novel, natural approach to treating less-commonly researched ailments. Caribbean Blue Scorpion venom has long had some popular medicinal use among people in several nations, and PreveCeutical’s aim is to provide a consistent, high-quality source that doesn’t require someone to milk scorpions regularly in order to establish a supply.
The company completed its first phase of R&D on the project earlier this year, identifying eight scorpion peptides of such a size and nature that PreveCeutical could redesign and synthesize them for potential use in Nature Identical™ products. The company has now begun Phase 2 of the project, which involves doing the peptide redesign work with the goal of improving the peptides’ stability, so they can maintain their potency while being employed against the brain maladies, according to a news release issued on July 31, 2018 (http://nnw.fm/zRQ3i).
“The Company’s research team is using state-of-the-art computer technology for its in-silico modelling and docking studies, against known brain cancer targets (e.g. Matrix metalloproteinases) to determine the structural features and amino acid sequences critical to their binding,” the news release states.
Once PreveCeutical establishes a library of highly stable peptides, the company will begin the third phase of the program in which it begins screening the Nature Identical™ peptides in cell-based glioblastoma models.
One of the company’s primary goals is to establish a novel drug delivery method by producing a Sol-gel compound that can be administered nasally, creating a pathway for medicines such as cannabidiol contained within the Sol-gel to reach the brain directly from the nose without having to travel the digestive tract and risking its weeding-out barriers.
Crystal Equity Research noted that the company shifted its potential “into a higher gear with its development pipeline” after successfully raising C$6.5 million ($4.9 million) in June for useable capital (http://nnw.fm/4Yj7v), as well as executing a five-for-one stock split that created the potential for greater liquidity. The research firm anticipates that preventative health care will continue to be a lucrative market, citing Grand View Research’s forecast for generating $196.9 billion in revenue by 2024 with a 15 percent CAGR.
“The recent capital raise provides some assurance that the R&D budget has sufficient support to reach milestones or at least produce relevant results,” Crystal Equity states.
For more information, visit the company’s website at www.PreveCeutical.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)